Selected research
Market Analysis & Forecast
Global Dry Age-Related Macular Degeneration Market Analysis and Forecast 2026-2032
Market perspective
The global Dry Age-Related Macular Degeneration market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Dry Age-Related Macular Degeneration is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Dry Age-Related Macular Degeneration is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for Dry Age-Related Macular Degeneration is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for Dry Age-Related Macular Degeneration is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of Dry Age-Related Macular Degeneration include Santen Pharmaceuticals, Y2 Solution, Stealth Biotherapeutics, Phio Pharmaceuticals, Ocumension Therapeutics, Kubota Vision, Iveric Bio, Eyestem Research and Belite Bio, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Dry Age-Related Macular Degeneration, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Dry Age-Related Macular Degeneration, also provides the revenue of main regions and countries. Of the upcoming market potential for Dry Age-Related Macular Degeneration, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Dry Age-Related Macular Degeneration revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Dry Age-Related Macular Degeneration market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Dry Age-Related Macular Degeneration revenue, projected growth trends, production technology, application and end-user industry.
Dry Age-Related Macular Degeneration Segment by Company
Santen Pharmaceuticals
Y2 Solution
Stealth Biotherapeutics
Phio Pharmaceuticals
Ocumension Therapeutics
Kubota Vision
Iveric Bio
Eyestem Research
Belite Bio
Bausch Health
Allergan
Alimera Science
Dry Age-Related Macular Degeneration Segment by Type
Oral
Injectables
Dry Age-Related Macular Degeneration Segment by Application
Above 40 Years
Above 60 Years
Above 75 Years
Dry Age-Related Macular Degeneration Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dry Age-Related Macular Degeneration market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Dry Age-Related Macular Degeneration and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dry Age-Related Macular Degeneration.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Dry Age-Related Macular Degeneration in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Dry Age-Related Macular Degeneration company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Dry Age-Related Macular Degeneration revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oral
- Injectables
Applications
- Above 40 Years
- Above 60 Years
- Above 75 Years
Companies covered
- Santen Pharmaceuticals
- Y2 Solution
- Stealth Biotherapeutics
- Phio Pharmaceuticals
- Ocumension Therapeutics
- Kubota Vision
- Iveric Bio
- Eyestem Research
- Belite Bio
- Bausch Health
- Allergan
- Alimera Science
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Dry Age-Related Macular Degeneration Market by Type
- 1.2.1 Global Dry Age-Related Macular Degeneration Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 Oral
- 1.2.3 Injectables
- 1.3 Dry Age-Related Macular Degeneration Market by Application
- 1.3.1 Global Dry Age-Related Macular Degeneration Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Above 40 Years
- 1.3.3 Above 60 Years
- 1.3.4 Above 75 Years
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Dry Age-Related Macular Degeneration Market Dynamics
- 2.1 Dry Age-Related Macular Degeneration Industry Trends
- 2.2 Dry Age-Related Macular Degeneration Industry Drivers
- 2.3 Dry Age-Related Macular Degeneration Industry Opportunities and Challenges
- 2.4 Dry Age-Related Macular Degeneration Industry Restraints
3 Global Growth Perspective
- 3.1 Global Dry Age-Related Macular Degeneration Market Perspective (2021-2032)
- 3.2 Global Dry Age-Related Macular Degeneration Growth Trends by Region
- 3.2.1 Global Dry Age-Related Macular Degeneration Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Dry Age-Related Macular Degeneration Market Size by Region (2021-2026)
- 3.2.3 Global Dry Age-Related Macular Degeneration Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global Dry Age-Related Macular Degeneration Revenue by Players
- 4.1.1 Global Dry Age-Related Macular Degeneration Revenue by Players (2021-2026)
- 4.1.2 Global Dry Age-Related Macular Degeneration Revenue Market Share by Players (2021-2026)
- 4.1.3 Global Dry Age-Related Macular Degeneration Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Dry Age-Related Macular Degeneration Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global Dry Age-Related Macular Degeneration Key Players Headquarters & Area Served
- 4.4 Global Dry Age-Related Macular Degeneration Players, Product Type & Application
- 4.5 Global Dry Age-Related Macular Degeneration Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global Dry Age-Related Macular Degeneration Market CR5 and HHI
- 4.6.3 2025 Dry Age-Related Macular Degeneration Tier 1, Tier 2, and Tier 3
5 Dry Age-Related Macular Degeneration Market Size by Type
- 5.1 Global Dry Age-Related Macular Degeneration Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global Dry Age-Related Macular Degeneration Revenue by Type (2021-2032)
- 5.3 Global Dry Age-Related Macular Degeneration Revenue Market Share by Type (2021-2032)
6 Dry Age-Related Macular Degeneration Market Size by Application
- 6.1 Global Dry Age-Related Macular Degeneration Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global Dry Age-Related Macular Degeneration Revenue by Application (2021-2032)
- 6.3 Global Dry Age-Related Macular Degeneration Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 Santen Pharmaceuticals
- 7.1.1 Santen Pharmaceuticals Company Information
- 7.1.2 Santen Pharmaceuticals Business Overview
- 7.1.3 Santen Pharmaceuticals Dry Age-Related Macular Degeneration Revenue and Gross Margin (2021-2026)
- 7.1.4 Santen Pharmaceuticals Dry Age-Related Macular Degeneration Product Portfolio
- 7.1.5 Santen Pharmaceuticals Recent Developments
- 7.2 Y2 Solution
- 7.2.1 Y2 Solution Company Information
- 7.2.2 Y2 Solution Business Overview
- 7.2.3 Y2 Solution Dry Age-Related Macular Degeneration Revenue and Gross Margin (2021-2026)
- 7.2.4 Y2 Solution Dry Age-Related Macular Degeneration Product Portfolio
- 7.2.5 Y2 Solution Recent Developments
- 7.3 Stealth Biotherapeutics
- 7.3.1 Stealth Biotherapeutics Company Information
- 7.3.2 Stealth Biotherapeutics Business Overview
- 7.3.3 Stealth Biotherapeutics Dry Age-Related Macular Degeneration Revenue and Gross Margin (2021-2026)
- 7.3.4 Stealth Biotherapeutics Dry Age-Related Macular Degeneration Product Portfolio
- 7.3.5 Stealth Biotherapeutics Recent Developments
- 7.4 Phio Pharmaceuticals
- 7.4.1 Phio Pharmaceuticals Company Information
- 7.4.2 Phio Pharmaceuticals Business Overview
- 7.4.3 Phio Pharmaceuticals Dry Age-Related Macular Degeneration Revenue and Gross Margin (2021-2026)
- 7.4.4 Phio Pharmaceuticals Dry Age-Related Macular Degeneration Product Portfolio
- 7.4.5 Phio Pharmaceuticals Recent Developments
- 7.5 Ocumension Therapeutics
- 7.5.1 Ocumension Therapeutics Company Information
- 7.5.2 Ocumension Therapeutics Business Overview
- 7.5.3 Ocumension Therapeutics Dry Age-Related Macular Degeneration Revenue and Gross Margin (2021-2026)
- 7.5.4 Ocumension Therapeutics Dry Age-Related Macular Degeneration Product Portfolio
- 7.5.5 Ocumension Therapeutics Recent Developments
- 7.6 Kubota Vision
- 7.6.1 Kubota Vision Company Information
- 7.6.2 Kubota Vision Business Overview
- 7.6.3 Kubota Vision Dry Age-Related Macular Degeneration Revenue and Gross Margin (2021-2026)
- 7.6.4 Kubota Vision Dry Age-Related Macular Degeneration Product Portfolio
- 7.6.5 Kubota Vision Recent Developments
- 7.7 Iveric Bio
- 7.7.1 Iveric Bio Company Information
- 7.7.2 Iveric Bio Business Overview
- 7.7.3 Iveric Bio Dry Age-Related Macular Degeneration Revenue and Gross Margin (2021-2026)
- 7.7.4 Iveric Bio Dry Age-Related Macular Degeneration Product Portfolio
- 7.7.5 Iveric Bio Recent Developments
- 7.8 Eyestem Research
- 7.8.1 Eyestem Research Company Information
- 7.8.2 Eyestem Research Business Overview
- 7.8.3 Eyestem Research Dry Age-Related Macular Degeneration Revenue and Gross Margin (2021-2026)
- 7.8.4 Eyestem Research Dry Age-Related Macular Degeneration Product Portfolio
- 7.8.5 Eyestem Research Recent Developments
- 7.9 Belite Bio
- 7.9.1 Belite Bio Company Information
- 7.9.2 Belite Bio Business Overview
- 7.9.3 Belite Bio Dry Age-Related Macular Degeneration Revenue and Gross Margin (2021-2026)
- 7.9.4 Belite Bio Dry Age-Related Macular Degeneration Product Portfolio
- 7.9.5 Belite Bio Recent Developments
- 7.10 Bausch Health
- 7.10.1 Bausch Health Company Information
- 7.10.2 Bausch Health Business Overview
- 7.10.3 Bausch Health Dry Age-Related Macular Degeneration Revenue and Gross Margin (2021-2026)
- 7.10.4 Bausch Health Dry Age-Related Macular Degeneration Product Portfolio
- 7.10.5 Bausch Health Recent Developments
- 7.11 Allergan
- 7.11.1 Allergan Company Information
- 7.11.2 Allergan Business Overview
- 7.11.3 Allergan Dry Age-Related Macular Degeneration Revenue and Gross Margin (2021-2026)
- 7.11.4 Allergan Dry Age-Related Macular Degeneration Product Portfolio
- 7.11.5 Allergan Recent Developments
- 7.12 Alimera Science
- 7.12.1 Alimera Science Company Information
- 7.12.2 Alimera Science Business Overview
- 7.12.3 Alimera Science Dry Age-Related Macular Degeneration Revenue and Gross Margin (2021-2026)
- 7.12.4 Alimera Science Dry Age-Related Macular Degeneration Product Portfolio
- 7.12.5 Alimera Science Recent Developments
8 North America
- 8.1 North America Dry Age-Related Macular Degeneration Revenue (2021-2032)
- 8.2 North America Dry Age-Related Macular Degeneration Revenue by Type (2021-2032)
- 8.2.1 North America Dry Age-Related Macular Degeneration Revenue by Type (2021-2026)
- 8.2.2 North America Dry Age-Related Macular Degeneration Revenue by Type (2027-2032)
- 8.3 North America Dry Age-Related Macular Degeneration Revenue Share by Type (2021-2032)
- 8.4 North America Dry Age-Related Macular Degeneration Revenue by Application (2021-2032)
- 8.4.1 North America Dry Age-Related Macular Degeneration Revenue by Application (2021-2026)
- 8.4.2 North America Dry Age-Related Macular Degeneration Revenue by Application (2027-2032)
- 8.5 North America Dry Age-Related Macular Degeneration Revenue Share by Application (2021-2032)
- 8.6 North America Dry Age-Related Macular Degeneration Revenue by Country
- 8.6.1 North America Dry Age-Related Macular Degeneration Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America Dry Age-Related Macular Degeneration Revenue by Country (2021-2026)
- 8.6.3 North America Dry Age-Related Macular Degeneration Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
9 Europe
- 9.1 Europe Dry Age-Related Macular Degeneration Revenue (2021-2032)
- 9.2 Europe Dry Age-Related Macular Degeneration Revenue by Type (2021-2032)
- 9.2.1 Europe Dry Age-Related Macular Degeneration Revenue by Type (2021-2026)
- 9.2.2 Europe Dry Age-Related Macular Degeneration Revenue by Type (2027-2032)
- 9.3 Europe Dry Age-Related Macular Degeneration Revenue Share by Type (2021-2032)
- 9.4 Europe Dry Age-Related Macular Degeneration Revenue by Application (2021-2032)
- 9.4.1 Europe Dry Age-Related Macular Degeneration Revenue by Application (2021-2026)
- 9.4.2 Europe Dry Age-Related Macular Degeneration Revenue by Application (2027-2032)
- 9.5 Europe Dry Age-Related Macular Degeneration Revenue Share by Application (2021-2032)
- 9.6 Europe Dry Age-Related Macular Degeneration Revenue by Country
- 9.6.1 Europe Dry Age-Related Macular Degeneration Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe Dry Age-Related Macular Degeneration Revenue by Country (2021-2026)
- 9.6.3 Europe Dry Age-Related Macular Degeneration Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Netherlands
10 China
- 10.1 China Dry Age-Related Macular Degeneration Revenue (2021-2032)
- 10.2 China Dry Age-Related Macular Degeneration Revenue by Type (2021-2032)
- 10.2.1 China Dry Age-Related Macular Degeneration Revenue by Type (2021-2026)
- 10.2.2 China Dry Age-Related Macular Degeneration Revenue by Type (2027-2032)
- 10.3 China Dry Age-Related Macular Degeneration Revenue Share by Type (2021-2032)
- 10.4 China Dry Age-Related Macular Degeneration Revenue by Application (2021-2032)
- 10.4.1 China Dry Age-Related Macular Degeneration Revenue by Application (2021-2026)
- 10.4.2 China Dry Age-Related Macular Degeneration Revenue by Application (2027-2032)
- 10.5 China Dry Age-Related Macular Degeneration Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Dry Age-Related Macular Degeneration Revenue (2021-2032)
- 11.2 Asia Dry Age-Related Macular Degeneration Revenue by Type (2021-2032)
- 11.2.1 Asia Dry Age-Related Macular Degeneration Revenue by Type (2021-2026)
- 11.2.2 Asia Dry Age-Related Macular Degeneration Revenue by Type (2027-2032)
- 11.3 Asia Dry Age-Related Macular Degeneration Revenue Share by Type (2021-2032)
- 11.4 Asia Dry Age-Related Macular Degeneration Revenue by Application (2021-2032)
- 11.4.1 Asia Dry Age-Related Macular Degeneration Revenue by Application (2021-2026)
- 11.4.2 Asia Dry Age-Related Macular Degeneration Revenue by Application (2027-2032)
- 11.5 Asia Dry Age-Related Macular Degeneration Revenue Share by Application (2021-2032)
- 11.6 Asia Dry Age-Related Macular Degeneration Revenue by Country
- 11.6.1 Asia Dry Age-Related Macular Degeneration Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia Dry Age-Related Macular Degeneration Revenue by Country (2021-2026)
- 11.6.3 Asia Dry Age-Related Macular Degeneration Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Dry Age-Related Macular Degeneration Revenue (2021-2032)
- 12.2 SAMEA Dry Age-Related Macular Degeneration Revenue by Type (2021-2032)
- 12.2.1 SAMEA Dry Age-Related Macular Degeneration Revenue by Type (2021-2026)
- 12.2.2 SAMEA Dry Age-Related Macular Degeneration Revenue by Type (2027-2032)
- 12.3 SAMEA Dry Age-Related Macular Degeneration Revenue Share by Type (2021-2032)
- 12.4 SAMEA Dry Age-Related Macular Degeneration Revenue by Application (2021-2032)
- 12.4.1 SAMEA Dry Age-Related Macular Degeneration Revenue by Application (2021-2026)
- 12.4.2 SAMEA Dry Age-Related Macular Degeneration Revenue by Application (2027-2032)
- 12.5 SAMEA Dry Age-Related Macular Degeneration Revenue Share by Application (2021-2032)
- 12.6 SAMEA Dry Age-Related Macular Degeneration Revenue by Country
- 12.6.1 SAMEA Dry Age-Related Macular Degeneration Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA Dry Age-Related Macular Degeneration Revenue by Country (2021-2026)
- 12.6.3 SAMEA Dry Age-Related Macular Degeneration Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst